134 related articles for article (PubMed ID: 34698689)
1. Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma.
Su MH; Wu HH; Huang HY; Lee NR; Chang WH; Lin SC; Chen YJ; Wang PH
J Chin Med Assoc; 2022 Feb; 85(2):204-211. PubMed ID: 34698689
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
Einstein MH; Klobocista M; Hou JY; Lee S; Mutyala S; Mehta K; Reimers LL; Kuo DY; Huang GS; Goldberg GL
Gynecol Oncol; 2012 Jan; 124(1):26-30. PubMed ID: 22055846
[TBL] [Abstract][Full Text] [Related]
6. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
Lorusso D; Martinelli F; Mancini M; Sarno I; Ditto A; Raspagliesi F
Int J Gynecol Cancer; 2014 Sep; 24(7):1256-61. PubMed ID: 25078338
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K; van der Heijden E; Godfrey K; Naik R; Kucukmetin A; Bryant A; Das N; Lopes AD
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD006812. PubMed ID: 23450572
[TBL] [Abstract][Full Text] [Related]
10. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
[TBL] [Abstract][Full Text] [Related]
11. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Powell MA; Filiaci VL; Hensley ML; Huang HQ; Moore KN; Tewari KS; Copeland LJ; Secord AA; Mutch DG; Santin A; Warshal DP; Spirtos NM; DiSilvestro PA; Ioffe OB; Miller DS
J Clin Oncol; 2022 Mar; 40(9):968-977. PubMed ID: 35007153
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Ebata T; Yonemori K; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Fujiwara Y; Kato T; Hasegawa K; Fujiwara K; Tamura K
Oncology; 2020; 98(10):699-705. PubMed ID: 32526764
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
Lacour RA; Euscher E; Atkinson EN; Sun CC; Ramirez PT; Coleman RL; Brown J; Gano JB; Burke TW; Ramondetta LM
Int J Gynecol Cancer; 2011 Apr; 21(3):517-22. PubMed ID: 21436700
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K; Godfrey K; Naik R; Kucukmetin A; Bryant A
Cochrane Database Syst Rev; 2011 Jan; (1):CD006812. PubMed ID: 21249682
[TBL] [Abstract][Full Text] [Related]
17. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Podzielinski I; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Matsuzaki S; Baba T; Satoh S; Shida M; Nishikawa T; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Fujiwara K; Hazama Y; Kadogami D; Moffitt MN; Takeuchi S; Nishimura M; Iwasaki K; Ushioda N; Johnson MS; Yoshida M; Hakam A; Li SW; Richmond AM; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Yamaguchi K; Oishi T; Kajiwara H; Hasegawa K; Yasuda M; Kawana K; Suda K; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Wakatsuki A; Sugiyama T; Pejovic T; Nagano T; Shimoya K; Andoh M; Shiki Y; Enomoto T; Sasaki T; Fujiwara K; Mikami M; Shimada M; Konishi I; Kimura T; Post MD; Shahzad MM; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Oncol; 2016 Jul; 27(7):1257-66. PubMed ID: 27052653
[TBL] [Abstract][Full Text] [Related]
18. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Park JH; Lee JL
Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
[TBL] [Abstract][Full Text] [Related]
19. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Krege S; Rembrink V; Börgermann C; Otto T; Rübben H
J Urol; 2001 Jan; 165(1):67-71. PubMed ID: 11125366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]